PRAME: From diagnostic marker and tumor antigen to promising target of RNAi therapy in leukemic cells

Leukemia Research

Volumn 35, Issue 9, 2011, Pages 1159-1160

  Yin, Bu ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Apoptosis; Cell cycle arrest; PRAME; Relapse; Targeting PRAME

Indexed keywords

BCR ABL PROTEIN; PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA; SMALL INTERFERING RNA; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

BLAST CELL CRISIS; CANCER IMMUNOTHERAPY; CELL CYCLE PROGRESSION; CELL SURVIVAL; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; DISEASE MARKER; EDITORIAL; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE SILENCING; GENE TARGETING; HUMAN; LEUKEMIA CELL; PRAME GENE; PRIORITY JOURNAL; RNA INTERFERENCE;

ANTIGENS, NEOPLASM; APOPTOSIS; CELL CYCLE; HUMANS; LEUKEMIA; RNA, SMALL INTERFERING;

EID: 80051472948     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.04.018     Document Type: Editorial

References (15)

1. van Baren N., Chambost H., Ferrant A., et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol 1998, 102:1376-1379.
2. Wadelin F., Fulton J., McEwan P.A., et al. Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia. Mol Cancer 2010, 9:226.
3. Proto-Siqueira R., Figueiredo-Pontes L.L., Panepucci R.A., et al. PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma. Leuk Res 2006, 30:1333-1339.
4. Matsushita M., Yamazaki R., Kawakami Y. Quantitative analysis of PRAME for detection of minimal residual disease in leukemia. Methods Mol Med 2004, 97:267-275.
5. Faderl S., Talpaz M., Estrov Z., et al. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999, 131:207-219.
6. Watari K., Tojo A., Nagamura-Inoue T., et al. Identification of a melanoma antigen, PRAME, as a BCR/ABL-inducible gene. FEBS Lett 2000, 466:367-371.
7. Radich J.P., Dai H., Mao M., et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 2006, 103:2794-2799.
8. Tajeddine N., Gala J.L., Louis M., et al. Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspaseindependent cell death in vitro and reduces tumorigenicity in vivo. Cancer Res 2005, 65:7348-7355.
9. Goellner S., Steinbach D., Schenk T., et al. Childhood acute myelogenous leukaemia: association between PRAME, apoptosis- and MDR-related gene expression. Eur J Cancer 2006, 42:2807-2814.
10. Epping M.T., Wang L., Edel M.J., et al. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 2005, 122:835-847.
11. De Carvalho D.D., Binato R., Pereira W.O., et al. BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients. Oncogene 2011, 30:223-233.
12. Oehler V.G., Guthrie K.A., Cummings C.L., et al. The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. Blood 2009, 114:3299-3308.
13. Tajeddine N., Louis M., Vermylen C., et al. Tumor associated antigen PRAME is a marker of favorable prognosis in childhood acute myeloid leukemia patients and modifies the expression of S100A4, Hsp 27, p21, IL-8 and IGFBP-2 in vitro and in vivo. Leuk Lymphoma 2008, 49:1123-1131.
14. Luetkens T., Schafhausen P., Uhlich F., et al. Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia. Leuk Res 2010, 34:1647-1655.
15. Tanaka N., Wang Y.-H., Shiseki M., Takanashi M., Motoji T. Inhibition of PRAME expression causes cell arrest and apoptosis in leukemic cells. Leuk Res 2011, 35:1219-1225.